The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar

TL;DR


Summary:
- The Global Fund, a major international health financing organization, plans to roll out a new twice-yearly injectable HIV treatment called cabotegravir in sub-Saharan Africa, regardless of whether the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program participates.
- The injectable treatment is seen as a game-changer, as it can improve adherence and reduce the stigma associated with daily oral HIV medication.
- The rollout of the injectable treatment is expected to significantly impact the fight against HIV/AIDS in sub-Saharan Africa, where the majority of people living with HIV reside.

Like summarized versions? Support us on Patreon!